Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study

PHASE2RecruitingINTERVENTIONAL

Enrollment

140

Participants

Timeline

Start Date

May 8, 2025

Primary Completion Date

August 31, 2029

Study Completion Date

August 31, 2031

Conditions

Acute Myeloid Leukemia (AML)

Interventions

DRUG

DMSA

Given PO

DRUG

Ca-EDTA

Given by IV

DRUG

Magnesium Sulfate

Given by infusion

DRUG

Multivitamin

Given PO

Trial Locations (1)

RECRUITING

The University of Texas M. D. Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER